For a company with relatively modest underlying growth trends, C.R.Bard (NYSE:BCR) has generated a fair bit of enthusiasm on the Street for the enhanced growth prospects bought through M&A and the royalty stream from Gore. Among the acquired products, investors are particularly keen on the prospects for the Lutonix drug-coated balloon and management's comments on the earnings call only seemed to add more confusion to already noisy situation. Bard is not a particularly cheap stock at these levels and the company is going to need better organic growth and clear differentiation in drug-coated balloons to support further gains.
A Lot Of Moving Parts For A Basically In-Line Quarter
Bard reported 8% revenue growth for the first quarter,...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|